question_id,date,category,question_text,baseline_success,baseline_actually_answered,baseline_has_expected,baseline_confidence,baseline_text,baseline_error,baseline_time,baseline_input_tokens,baseline_output_tokens,togomcp_success,togomcp_has_expected,togomcp_confidence,togomcp_text,togomcp_error,togomcp_time,togomcp_input_tokens,togomcp_output_tokens,togomcp_cache_creation_input_tokens,togomcp_cache_read_input_tokens,tools_used,tool_details,value_add,expected_answer,notes
121,2025-12-23,Structured Query,Which antibiotics are likely effective against Enterococcus faecalis that is resistant to ampicillin and vancomycin but remains susceptible to gentamicin?,True,True,False,0.0,"For ampicillin- and vancomycin-resistant *Enterococcus faecalis* (VRE) that remains susceptible to gentamicin, treatment options are limited but include:

## Primary Options:

**1. Linezolid**
- Oxazolidinone class antibiotic
- Typically effective against VRE
- Bacteriostatic against enterococci
- Good tissue penetration

**2. Daptomycin**
- Lipopeptide antibiotic
- Bactericidal activity
- Higher doses (8-12 mg/kg) often needed for enterococcal infections
- NOT effective for pneumonia (inactivated by surfactant)

**3. Tigecycline**
- Glycylcycline antibiotic
- Usually active against VRE
- Limited by bacteriostatic activity and lower serum levels
- Better for intra-abdominal/soft tissue infections

## Combination Therapy Consideration:

**Gentamicin synergy with other agents:**
- Since this isolate is gentamicin-susceptible (unusual for high-level resistance), gentamicin could potentially be combined with:
  - Daptomycin
  - Linezolid
  - Other cell wall-active agents (if any partial activity exists)
- However, gentamicin alone is insufficient for enterococcal infections

## Important Notes:
- Formal susceptibility testing is essential to confirm activity
- Combination therapy may be warranted for serious infections (endocarditis, bacteremia)
- Newer agents like oritavancin or tedizolid may have activity but with less clinical data for enterococci

The specific choice depends on infection site, severity, and patient factors.",,11.056354999542236,75,409,True,False,0.0,"Based on the PubMed literature search, for **Enterococcus faecalis** that is resistant to both ampicillin and vancomycin but remains susceptible to gentamicin, the following antibiotics are likely to be effective:

## Recommended Treatment Options:

### 1. **Linezolid**
According to PubMed, linezolid is consistently mentioned as an effective option for vancomycin-resistant enterococci (VRE). [DOI](https://doi.org/10.3855/jidc.21399) This oxazolidinone antibiotic is bacteriostatic and maintains good activity against multidrug-resistant E. faecalis.

### 2. **Daptomycin**
Daptomycin is another important option for VRE infections and is often used for serious enterococcal infections including bacteremia and endocarditis when standard therapies fail.

### 3. **High-Level Gentamicin Synergy Combinations**
Since the strain remains susceptible to gentamicin, synergistic combination therapy may be considered:
- **Gentamicin + an alternative cell wall-active agent** (if any susceptibility exists to other beta-lactams)
- However, the studies indicate that high-level aminoglycoside resistance (HLA) is increasingly common (54.55% in E. faecalis according to one study [DOI](https://doi.org/10.3855/jidc.21399))

### 4. **Meropenem + Ceftaroline**
According to PubMed research, this combination showed significant activity against E. faecalis with penicillin MICs ≤2 μg/mL. The combination demonstrated enhanced killing with no regrowth or MIC increases [DOI](https://doi.org/10.1128/aac.00426-22). This may be considered as an alternative to ampicillin-based regimens.

### 5. **Nitrofurantoin** (for urinary tract infections only)
For UTIs specifically, nitrofurantoin showed 69.69% sensitivity against E. faecalis isolates [DOI](https://doi.org/10.3855/jidc.21399)

### 6. **Fosfomycin** (for urinary tract infections only)
For UTIs, fosfomycin demonstrated 78.79% sensitivity against E. faecalis [DOI](https://doi.org/10.3855/jidc.21399)

### 7. **Nitroxoline** (for urinary tract infections)
An in vitro study showed nitroxoline had favorable activity against E. faecalis and could be effective for uncomplicated UTIs [DOI](https://doi.org/10.1016/j.ijantimicag.2017.10.010)

## Important Considerations:

- The specific infection site matters significantly for treatment selection
- For **serious infections** (bacteremia, endocarditis): Linezolid or daptomycin are typically preferred
- For **urinary tract infections**: Nitrofurantoin, fosfomycin, or nitroxoline may be appropriate
- **Susceptibility testing** is critical given the high rates of resistance
- The studies noted concerning trends with E. faecalis resistance to ampicillin and vancomycin being increasingly common [DOI](https://doi.org/10.18295/2075-0528.2904)

**Sources:**
- [Journal of Infection in Developing Countries](https://doi.org/10.3855/jidc.21399)
- [Antimicrobial Agents and Chemotherapy](https://doi.org/10.1128/aac.00426-22)
- [Sultan Qaboos University Medical Journal](https://doi.org/10.18295/2075-0528.2904)
- [International Journal of Antimicrobial Agents](https://doi.org/10.1016/j.ijantimicag.2017.10.010)",,41.23388075828552,15,1285,35518,47979,"mcp__pubmed__search_articles, mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""Enterococcus faecalis ampicillin vancomycin resistant treatment antibiotics"", ""max_results"": 20}}, {""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""VRE Enterococcus faecalis antimicrobial susceptibility alternative therapy"", ""max_results"": 20}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41358773"", ""41248470"", ""40979595"", ""40757887"", ""39950002"", ""36154173"", ""32138506"", ""29111434""]}}]",VALUABLE,Doxycycline and linezolid.,"Database: BacDive. Tests complex filtering with multiple antibiotic susceptibility criteria: (1) organism = Enterococcus faecalis, (2) resistant to ampicillin, (3) resistant to vancomycin, (4) susceptible to gentamicin, (5) identify other effective antibiotics. Requires structured database query to filter strain-specific antimicrobial susceptibility data. Baseline cannot perform such specific susceptibility pattern filtering. This represents a realistic clinical microbiology question for antibiotic selection."
122,2025-12-23,Structured Query,Is Helicobacter pylori that is resistant to clarithromycin and levofloxacin likely to remain susceptible to tetracycline?,True,True,True,1.0,"Yes, **Helicobacter pylori strains resistant to clarithromycin and levofloxacin are likely to remain susceptible to tetracycline**.

Here's why:

## Different Resistance Mechanisms

1. **Clarithromycin resistance**: Primarily caused by point mutations in the 23S rRNA gene (most commonly A2143G, A2142G, A2142C)

2. **Levofloxacin resistance**: Results from mutations in the quinolone resistance-determining regions (QRDR) of gyrA and, less commonly, gyrB genes

3. **Tetracycline resistance**: Caused by mutations in the 16S rRNA gene, particularly at positions 965-967 (AGA→TTC triple mutation)

## Key Points

- **Independent mechanisms**: Since these antibiotics have different molecular targets and distinct resistance mechanisms, resistance to one does not predict resistance to another

- **Low tetracycline resistance rates**: Tetracycline resistance in H. pylori remains relatively rare globally (typically <5% in most regions), even in areas with high clarithromycin and fluoroquinolone resistance

- **No cross-resistance**: There is no known cross-resistance between these antibiotic classes

## Clinical Relevance

This is why **bismuth quadruple therapy** (containing tetracycline) is often used as rescue therapy after failure of clarithromycin- or levofloxacin-based regimens. Tetracycline remains a reliable option even when resistance to other antibiotics is present.

However, susceptibility testing when available is always ideal to confirm this assumption.",,10.182382106781006,72,374,True,True,1.0,"Based on recent research from PubMed, **yes, H. pylori strains resistant to clarithromycin and levofloxacin are very likely to remain susceptible to tetracycline**. Here's what the data shows:

## Key Findings on Tetracycline Resistance

1. **Extremely Low Tetracycline Resistance Rates:**
   - A 2025 Taiwan study found only **0.8% tetracycline resistance** overall, despite 18.0% clarithromycin resistance and 28.7% levofloxacin resistance ([DOI](https://doi.org/10.3748/wjg.v31.i39.111380))
   - In a Taiwan refractory infection cohort with 89.9% clarithromycin resistance and 86.2% levofloxacin resistance, tetracycline resistance was only **15.6%** ([DOI](https://doi.org/10.1177/17562848251404379))
   - Chinese Yi population study showed **0.4% tetracycline resistance** vs 22.9% clarithromycin and 39.7% levofloxacin resistance ([DOI](https://doi.org/10.1093/infdis/jiaf411))

2. **Independent Resistance Mechanisms:**
   The low correlation between tetracycline resistance and clarithromycin/levofloxacin resistance suggests these antibiotics have different resistance mechanisms:
   - **Clarithromycin resistance**: Primarily 23S rRNA mutations
   - **Levofloxacin resistance**: DNA gyrase mutations
   - **Tetracycline resistance**: Rare, different mechanism

3. **Clinical Implications:**
   Multiple studies recommend tetracycline-based regimens (like bismuth-tetracycline-metronidazole quadruple therapy) specifically because tetracycline maintains high susceptibility even in multi-drug resistant strains.

## Important Caveat

While tetracycline resistance is generally very low, the Taiwan longitudinal study noted a concerning trend: tetracycline resistance increased from **0% in 2019 to 3.5% in 2024** ([DOI](https://doi.org/10.3748/wjg.v31.i39.111380)), suggesting this may be changing over time in some regions.

**Bottom line:** Tetracycline remains highly effective even against clarithromycin- and levofloxacin-resistant H. pylori, making it an excellent choice for rescue therapy after treatment failures.",,44.82811903953552,12,872,39302,47301,"mcp__pubmed__search_articles, mcp__pubmed__get_article_metadata","[{""name"": ""mcp__pubmed__search_articles"", ""input"": {""query"": ""Helicobacter pylori clarithromycin levofloxacin tetracycline resistance"", ""max_results"": 20, ""date_from"": ""2020""}}, {""name"": ""mcp__pubmed__get_article_metadata"", ""input"": {""pmids"": [""41424966"", ""41392259"", ""41361974"", ""41278167"", ""41264394"", ""41264393"", ""41202924"", ""41195999"", ""41180781"", ""41118015""]}}]",VALUABLE,Yes,"Database: BacDive. Tests querying antibiotic resistance patterns with multiple constraints: (1) organism = Helicobacter pylori, (2) resistant to clarithromycin, (3) resistant to levofloxacin, (4) check tetracycline susceptibility. Requires structured search and filtering of antimicrobial susceptibility data across different resistance patterns. Baseline knowledge may have general information about H. pylori resistance but cannot query specific strain-level susceptibility patterns from database. This is a clinically relevant question for treatment planning in multi-drug resistant H. pylori infections."
